立体定向放射外科治疗脑海绵状血管畸形的系统评价
该系统评价纳入30项队列研究共1576例接受立体定向放射外科(SRS)治疗的脑海绵状血管畸形(CCM)患者,中位随访48个月,年死亡率0.18%、年症状性颅内出血率2.40%、年持续性局灶神经功能缺损率0.71%,复合终点年发生率3.63%,与未接受SRS的结局似乎相当,但缺乏随机对照证据。
要点
- SRS治疗后年死亡率0.18%、症状性颅内出血率2.40%、持续性局灶神经功能缺损率0.71%。
- 复合终点(死亡、颅内出血或持续性局灶神经功能缺损)年发生率为3.63%。
- 结局不因CCM位置或SRS类型而异,但现有证据不足以证明SRS优于显微手术或保守治疗。
核心结论
- SRS治疗CCM后年死亡、颅内出血和持续性局灶神经功能缺损发生率均低于5%,似乎与未接受SRS的结局相当。
- 比较性研究未显示SRS与其他治疗策略之间存在显著关联,仍需随机对照试验验证。
研究设计与样本
- 系统评价检索Ovid Medline和Ovid EMBASE自建库至2018年6月1日的同行评议文献。
- 纳入报告≥10例CCM患者SRS后临床结局的队列研究,不论有无神经外科切除或保守治疗的比较组。
- 共纳入30项队列研究,合计1576例接受SRS治疗的CCM患者。
- 其中4项非随机研究比较了SRS与其他治疗策略,但未显示显著关联。
主要发现
- SRS后中位随访48个月(四分位距35-62个月)。
- 年死亡率0.18%(95%CI 0.10-0.31)。
- 年症状性颅内出血发生率2.40%(95%CI 2.05-2.80)。
- 年持续性局灶神经功能缺损发生率0.71%(95%CI 0.53-0.96)。
- 年复合终点(死亡、颅内出血或持续性局灶神经功能缺损)发生率3.63%(95%CI 3.17-4.16)。
临床怎么用
- 对于CCM患者,SRS后年严重不良事件发生率较低,可作为个体化治疗决策的参考。
- 现有证据尚不能证明SRS优于显微手术切除或保守治疗,选择SRS需谨慎评估。
局限性
- 纳入研究均为队列研究,缺乏随机对照试验证据。
- 比较性研究未显示SRS与其他治疗策略的显著关联,无法排除混杂因素。
- 随访时间中位48个月,长期结局尚不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The efficacy of stereotactic radiosurgery (SRS) for the treatment of cerebral cavernous malformations (CCMs) is uncertain, so we set out to quantify clinical outcomes after SRS for CCM and compare them to microsurgical excision or conservative management. METHODS: We searched Ovid Medline and Ovid EMBASE from inception until June 1, 2018, for peer-reviewed publications describing clinical outcomes after SRS for ≥10 people with CCM in cohorts with or without a comparison group treated with neurosurgical excision or conservative management. Two reviewers independently extracted data from the included studies to quantify cohort characteristics and the incidence of the primary outcome (death attributable to CCM or its treatment) and secondary outcomes (incident nonfatal symptomatic intracerebral hemorrhage [ICH] and incident nonhemorrhagic persistent focal neurologic deficit [FND]). We assessed whether comparative studies showed a dramatic association (meaning the conventionally calculated probability comparing 2 differently managed patient groups from the same population was <0.01 with a rate ratio greater than 10). RESULTS: We included 30 cohort studies involving a total of 1,576 patients undergoing SRS for CCM. Four nonrandomized studies compared SRS to other treatment strategies, but did not demonstrate dramatic associations. During a median follow-up of 48 (interquartile range 35-62) months after SRS, the annual incidences (95% confidence interval) of outcomes were death 0.18% (0.10-0.31), ICH 2.40% (2.05-2.80), FND 0.71% (0.53-0.96), and the composite of death, ICH, or FND 3.63% (3.17-4.16). Outcomes did not differ by CCM location or type of SRS. CONCLUSION: After SRS for CCM, the annual incidences of death, ICH, and FND are <5% and seem comparable to outcomes without SRS. A randomized trial of SRS for CCM is needed.
引用
- Poorthuis MHF, Rinkel LA, Lammy S, et al. Stereotactic radiosurgery for cerebral cavernous malformations: A systematic review. Neurology. 2019. PMID: 31659093. doi:10.1212/WNL.0000000000008521
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。